down arrow

Unity Biotechnology, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US91381U2006
USD
0.06
0 (0.36%)

Oct 01

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.060.06

52 Week

0.053.10
Valuation
Technical
Day's Volume

CASH

71.71 k

Shareholding (Mar 2025)

FII

0.38%

Held by 9 FIIs

DII

87.7%

Held by 6 DIIs

Promoter

6.33%

How big is Unity Biotechnology, Inc.?

22-Jun-2025

As of Jun 18, Unity Biotechnology, Inc. has a market capitalization of 13.36 million and reported net sales of 0.00 million with a net profit of -27.50 million over the last four quarters. The balance sheet shows shareholder's funds of 6.49 million and total assets of 40.41 million.

As of Jun 18, Unity Biotechnology, Inc. has a market capitalization of 13.36 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -27.50 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 6.49 million and total assets amounting to 40.41 million.

Read More

What does Unity Biotechnology, Inc. do?

22-Jun-2025

Unity Biotechnology, Inc. is a clinical stage biotechnology company focused on developing therapeutics for aging-related diseases. It has a market cap of $13.36 million and reported a net profit loss of $7 million as of March 2025.

Overview: <BR>Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing-related diseases within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 13.36 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 13.03 <BR>Return on Equity: 2,972.40% <BR>Price to Book: -13.36<BR><BR>Contact Details: <BR>Address: 3280 Bayshore Blvd, BRISBANE CA: 94005-1028 <BR>Tel: 1 650 4161192 <BR>Website: https://unitybiotechnology.com/

Read More

Who are in the management team of Unity Biotechnology, Inc.?

22-Jun-2025

As of March 2022, the management team of Unity Biotechnology, Inc. includes Chairman Keith Leonard, CEO Anirvan Ghosh, President Nathaniel David, and several directors with diverse expertise, including Mary Campbell, Robert Nelsen, Gilmore O'Neill, Luis Visoso, and independent director Paul Berns.

As of March 2022, the management team of Unity Biotechnology, Inc. includes the following individuals:<BR><BR>- Mr. Keith Leonard, Chairman of the Board<BR>- Dr. Nathaniel David, President, Co-Founder, and Director<BR>- Dr. Anirvan Ghosh, Chief Executive Officer and Director<BR>- Dr. Mary Campbell, Director<BR>- Mr. Robert Nelsen, Director<BR>- Dr. Gilmore O'Neill, Director<BR>- Mr. Luis Visoso, Director<BR>- Mr. Paul Berns, Independent Director<BR><BR>This team comprises a mix of leadership roles, with expertise in various areas relevant to the company's focus.

Read More

Is Unity Biotechnology, Inc. overvalued or undervalued?

25-Jun-2025

As of March 15, 2023, Unity Biotechnology, Inc. has been downgraded to "does not qualify" due to being overvalued with a negative price-to-book value of -11.72 and an EV to EBIT ratio of 0.04, while its stock has underperformed the S&P 500 with a year-to-date return of -23.19%.

As of 15 March 2023, the valuation grade for Unity Biotechnology, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its financial standing. The company is currently assessed as overvalued, particularly given its negative price-to-book value of -11.72 and an EV to EBIT ratio of 0.04, which suggests minimal enterprise value relative to earnings before interest and taxes. Additionally, the ROCE stands at an impressive 234.34%, but this is overshadowed by the overall financial instability reflected in the other ratios.<BR><BR>In comparison to its peers, Unity Biotechnology's valuation metrics are concerning. For instance, MAIA Biotechnology, Inc. has a valuation of -2.7810 with an EV to EBITDA of -2.1328, while MiNK Therapeutics, Inc. shows a valuation of -3.3419 with an EV to EBITDA of -3.4718. These comparisons highlight that Unity's financial ratios do not stand favorably against its industry counterparts. Furthermore, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -23.19% compared to the index's 2.44%, reinforcing the notion that Unity is currently overvalued.

Read More

Is Unity Biotechnology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Unity Biotechnology, Inc. shows a mildly bearish trend with mixed technical indicators, including mildly bullish MACD and RSI on weekly charts but bearish signals on daily moving averages and KST, while significantly underperforming the S&P 500 with a year-to-date return of -93.85%.

As of 4 September 2025, the technical trend for Unity Biotechnology, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. The weekly RSI is bullish, but the monthly RSI is bearish, suggesting mixed signals. Daily moving averages are bearish, and both the weekly and monthly KST are bearish, indicating underlying weakness. The OBV shows a mildly bullish stance on the weekly timeframe, but no trend on the monthly. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -93.85% compared to the S&P 500's 12.22%, and a one-year return of -95.77% versus 17.14%. Overall, the current technical stance is mildly bearish, driven by the mixed indicators and significant underperformance relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

13.03

stock-summary
Return on Equity

2,972.40%

stock-summary
Price to Book

-1.03

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-83.65%
0%
-83.65%
6 Months
-94.16%
0%
-94.16%
1 Year
-96.1%
0%
-96.1%
2 Years
-97.66%
0%
-97.66%
3 Years
-98.58%
0%
-98.58%
4 Years
-99.81%
0%
-99.81%
5 Years
-99.84%
0%
-99.84%

Unity Biotechnology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Unity Biotechnology, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Unity Biotechnology, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. The weekly RSI is bullish, but the monthly RSI is bearish, suggesting mixed signals. Daily moving averages are bearish, and both the weekly and monthly KST are bearish, indicating underlying weakness. The OBV shows a mildly bullish stance on the weekly timeframe, but no trend on the monthly. In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -93.85% compared to the S&P 500's 12.22%, and a one-year return of -95.77% versus 17.14%. Overall, the current technical stance is mildly bearish, driven by the mixed indicators and significant underperformance relative to the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
10.86%
EBIT to Interest (avg)
-44.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
13.03
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
25.26%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-11.72
EV to EBIT
0.04
EV to EBITDA
0.04
EV to Capital Employed
0.10
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
234.34%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Sideways
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (5.6%)

Foreign Institutions

Held by 9 Foreign Institutions (0.38%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 13.10% vs -29.23% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-7.10",
          "chgp": "5.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-1.40",
          "chgp": "57.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.30",
          "val2": "-8.40",
          "chgp": "13.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 34.84% vs 33.39% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.90",
          "val2": "-39.00",
          "chgp": "28.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.50",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.00",
          "val2": "1.20",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.00",
          "val2": "-39.90",
          "chgp": "34.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.70
-7.10
5.63%
Interest
0.00
0.00
Exceptional Items
-0.60
-1.40
57.14%
Consolidate Net Profit
-7.30
-8.40
13.10%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 13.10% vs -29.23% in Dec 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.90
-39.00
28.46%
Interest
0.00
2.50
-100.00%
Exceptional Items
1.00
1.20
-16.67%
Consolidate Net Profit
-26.00
-39.90
34.84%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 34.84% vs 33.39% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Unity Biotechnology, Inc. stock-summary
stock-summary
Unity Biotechnology, Inc.
Pharmaceuticals & Biotechnology
Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.
Company Coordinates stock-summary
Company Details
3280 Bayshore Blvd , BRISBANE CA : 94005-1028
stock-summary
Tel: 1 650 4161192
stock-summary
https://unitybiotechnology.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."